US FDA grants priority review to AstraZeneca’s sNDA for breast cancer therapy
AstraZeneca and Merck & Co (MSD) are together developing and commercialising Lynparza, a first-in-class PARP inhibitor. The sNDA was based on results obtained from the Phase III,